Cite
APA Citation
Jackson, D., Qiao, N., Greene, J., Hale, D., Berry, J., Trappey, A., Vreeland, T., Clifton, G., Ibrahim, N., Toms, A., Peoples, G., & Mittendorf, E. (2015). preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine. Journal for immunotherapy of cancer, 3(2), 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x000105